Heron Therapeutics Inc (HRTX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Barry D. Quart
Employees:
300
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA 92121
6503662626

Heron Therapeutics, Inc. engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy.

Data derived from most recent annual or quarterly report
Market Cap 179.521 Million Shares Outstanding118.888 Million Avg 30-day Volume 2.063 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.38
Price to Revenue4.7968 Debt to Equity6.9214 EBITDA-214.638 Million
Price to Book Value21.0032 Operating Margin-211.4365 Enterprise Value505.161 Million
Current Ratio2.384 EPS Growth0.126 Quick Ratio1.746
1 Yr BETA 1.8458 52-week High/Low 6.38 / 1.48 Profit Margin-220.5526
Operating Cash Flow Growth26.591 Altman Z-Score-9.7134 Free Cash Flow to Firm -136.522 Million
Earnings Report2023-05-08
View SEC Filings from HRTX instead.

View recent insider trading info

Heron Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding HRTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HRTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2023-03-02 by KOTLER KEVIN
  • 3: filed on 2023-03-02 by COLLARD CRAIG A
  • 4: filed on 2023-02-24 by MORGAN ADAM
  • 3: filed on 2023-02-08 by MORGAN ADAM
  • 3: filed on 2023-02-08 by RUBRIC CAPITAL MANAGEMENT LP
  • 4: filed on 2023-01-20 by SZEKERES DAVID LESLIE
  • 4: filed on 2023-01-20 by QUART BARRY D
  • 4: filed on 2023-01-20 by POYHONEN JOHN
  • 4: filed on 2023-01-20 by PERAZA LISA
  • 4: filed on 2023-01-20 by MANHARD KIMBERLY

    • Events (8k)

  • 8-K: filed on 2023-03-23:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-06:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-19:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-10:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    COLLARD CRAIG A

    • Director
    		 37,879 2023-02-22 1

    KOTLER KEVIN

    • Director
    		 577,879 2023-02-22 1

    MORGAN ADAM

    • Director
    • SEE NOTES 2 & 3
    		 4,537,879 2023-02-22 2

    VELAN CAPITAL INVESTMENT MANAGEMENT LP

    VELAN CAPITAL MASTER FUND LP

    VELAN CAPITAL HOLDINGS LLC

    VELAN CAPITAL MANAGEMENT LLC

    VENKATARAMAN BALAJI

    MORGAN ADAM

    • SEE FOOTNOTE 2SEE FOOTNOTE 2SEE FOOTNOTE 2SEE FOOTNOTE 2SEE FOOTNOTE 2SEE FOOTNOTE 2
    		 4,500,000 2023-01-30 2

    RUBRIC CAPITAL MANAGEMENT LP

    ROSEN DAVID EFRAIM

    • SEE FOOTNOTE 1SEE FOOTNOTE 1
    		 11,750,000 2023-01-30 1

    MANHARD KIMBERLY EVP, DRUG DEVELOPMENT

    • Officer
    • Director
    		 149,365 2023-01-18 7

    POYHONEN JOHN PRESIDENT & CCO

    • Officer
    		 66,385 2023-01-18 6

    QUART BARRY D CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 850,000 2023-01-18 5

    SZEKERES DAVID LESLIE EVP, CHIEF OPERATING OFFICER

    • Officer
    		 49,788 2023-01-18 6

    PERAZA LISA VP, CHIEF ACCOUNTING OFFICER

    • Officer
    		 42,631 2023-01-18 6

    DAVIS STEPHEN

    • Director
    		 129,192 2022-12-16 1

    JOHNSON CRAIG A

    • Director
    		 129,032 2022-12-16 1

    CHRISTIAN WAAGE

    • Director
    		 129,392 2022-12-16 1

    RODRIGUEZ SUSAN

    • Director
    		 132,442 2022-12-16 1

    DISSANAIKE SHARMILA

    • Director
    		 132,442 2022-12-16 1

    TANG KEVIN C

    • FORMER DIRECTOR
    		 No longer subject to file 2020-12-31 0

    HOFFMAN ROBERT CFO & SVP, FINANCE

    • Officer
    		 0 2019-12-19 0

    ROSEN ROBERT PRESIDENT

    • Officer
    • Director
    		 0 2018-12-15 0

    TANG KEVIN C

    TANG CAPITAL MANAGEMENT LLC

    TANG CAPITAL PARTNERS LP

    • Director
    • 10% Owner
    		 5,851,503 2018-09-12 0

    DRAZBA BRIAN G. VP, FINANCE & CFO

    • Officer
    		 3,798 2016-04-29 0

    MARSHALL PAUL SVP, TECHNICAL OPERATIONS

    • Officer
    		 2,200 2016-03-21 0

    CLENDENINN NEIL JAMES SVP & CHIEF MEDICAL OFFICER

    • Officer
    		 0 2015-10-12 0

    SPCH, LLC

    MIDLER ANDREW R

    • EXITING 10% HOLDEREXITING 10% HOLDER
    		 No longer subject to file 2014-12-31 0

    SAVITR CAPITAL, LLC

    • EXITING 10% HOLDER
    		 No longer subject to file 2014-12-31 0

    GELDER MARK S. MD SVP & CHIEF MEDICAL OFFICER

    • Officer
    		 0 2014-12-12 0

    WHELAN JOHN CFO

    • Officer
    		 254,088 2013-07-18 0

    ADAM MICHAEL A CHIEF OPERATING OFFICER

    • Officer
    		 0 2013-02-08 0

    SPCH, LLC

    • 10% Owner
    		 0 2013-01-01 0

    GODDARD PAUL

    • Director
    • CHAIRMAN
    		 0 2012-05-29 0

    TURNBULL GREG

    • Director
    		 0 2012-05-29 0

    BARR JOHN VICE PRESIDENT OF R&D

    • Officer
    		 0 2011-07-08 0

    BAKER BIOTECH CAPITAL (GP), LLC

    BAKER FELIX

    BAKER JULIAN

    • 10% Owner
    		 No longer subject to file 2011-07-01 0

    BAKER BROS. CAPITAL (GP), LLC

    BAKER JULIAN

    BAKER FELIX

    • 10% Owner
    		 No longer subject to file 2011-07-01 0

    BAKER / TISCH CAPITAL (GP), LLC

    BAKER FELIX

    BAKER JULIAN

    • 10% Owner
    		 No longer subject to file 2011-07-01 0

    BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

    BAKER JULIAN

    BAKER FELIX

    • 10% Owner
    		 No longer subject to file 2011-07-01 0

    14159 CAPITAL (GP), LLC

    BAKER JULIAN

    BAKER FELIX

    • 10% Owner
    		 No longer subject to file 2011-07-01 0

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    • 10% Owner
    		 26,666,667 2011-07-01 0

    ZERBE ROBERT L MD

    • Director
    		 202,072 2010-05-20 0

    ROSENBLATT TOBY

    • Director
    		 210,234 2010-05-20 0

    PRENTKI RONALD J PRESIDENT & CEO

    • Officer
    • Director
    		 0 2010-02-17 0

    TAYLOR ARTHUR T

    • Director
    		 15,000 2008-05-28 0

    RIEPENHAUSEN PETER

    • Director
    		 71,900 2008-02-28 0

    WHITEFORD STEPHEN V.P., FINANCE & CFO

    • Officer
    		 15,000 2006-12-15 0

    DRURY STEPHEN A

    • Director
    		 83,283 2006-08-11 0

    WINGER DENNIS L

    • Director
    		 69,544 2006-08-11 0

    OCONNELL MICHAEL CHIEF EXECUTIVE OFFICER

    • Officer
    		 45,000 2006-01-10 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    MORGAN ADAM - Director SEE NOTES 2 & 3

    		2023-02-24 19:20:31 -0500 2023-02-22 A 37,879 a 37,879 direct 2.1552 -0.431 3.0172 5 -0.431 6

    MORGAN ADAM - Director SEE NOTES 2 & 3

    		2023-02-24 19:20:31 -0500 2023-02-22 A 227,272 a 227,272 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    HERON THERAPEUTICS INC HRTX 2023-03-31 22:15:04 UTC 4.3898 0.4302 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 21:45:05 UTC 4.3898 0.4302 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 21:15:03 UTC 4.3654 0.4546 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 20:45:04 UTC 4.3654 0.4546 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 20:15:04 UTC 4.3654 0.4546 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 19:45:04 UTC 4.3654 0.4546 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 19:15:04 UTC 4.3654 0.4546 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 18:45:04 UTC 4.3654 0.4546 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 18:15:04 UTC 4.3654 0.4546 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 17:45:04 UTC 4.3654 0.4546 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 17:15:03 UTC 4.3654 0.4546 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 16:45:04 UTC 4.3715 0.4485 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 16:15:04 UTC 4.3715 0.4485 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 15:45:04 UTC 4.3715 0.4485 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 15:15:03 UTC 4.3715 0.4485 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 14:45:04 UTC 4.3715 0.4485 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 14:15:04 UTC 4.3715 0.4485 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 13:45:03 UTC 4.4009 0.4191 1400000
    HERON THERAPEUTICS INC HRTX 2023-03-31 13:15:03 UTC 4.4009 0.4191 1000000
    HERON THERAPEUTICS INC HRTX 2023-03-31 12:45:03 UTC 4.4009 0.4191 1000000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund HRTX -3500.0 shares, $-37415.0 2021-09-30 N-PORT
    Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio HRTX -47100.0 shares, $-503499.0 2021-09-30 N-PORT
    Federated Hermes Adviser Series- Federated Hermes MDT Market Neutral Fund HRTX -21601.0 shares, $-54002.5 2022-12-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund HRTX -9500.0 shares, $-23750.0 2022-12-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments